Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals

Medimetriks Adds Centany® (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio FAIRFIELD, N.J., Oct. 28 (HSMN NewsFeed) -- Medimetriks Pharmaceuticals announced today that the Company entered into a licensing agreement with Perrigo Company (Nasdaq: PRGO ) for the U.S. marketing rights to Centany® Ointment and two prescription keratolytic brands. Patented through 2018, Centany® represents an important step in Medimetriks' plan to commercialize patent-protected therapies for the Dermatology and Podiatry markets that offer important patient benefits. Medimetriks plans to launch Centany® in early 2009, with the two additional products following shortly thereafter. Previously marketed by Johnson & Johnson's OrthoNeutrogena professional division, Centany® is indicated for the topical treatment... [read full story]